ABCL
AbCellera BiologicsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The earnings update materially improved the near-term thesis versus the prior baseline because ABCL635 showed clean early safety, target engagement, and a monthly-dosing profile, while liquidity remained substantial enough to fund the next clinical milestones. That supports a cautious positive revision to the evidence base even though the stock is still waiting on Phase 2 efficacy.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.5.
What can break
ABCL635 still lacks the Phase 2 efficacy data that would more fully validate the pipeline pivot; disappointing Q3 2026 results would likely pressure the shares.
Momentum
93
Value
41
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.20 · Bull $7.50 · Bear $3.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $10.50
Why
Momentum93 · Δ7d -0.5
Value41 · Δ7d +0.1
Sentiment33 · Δ7d +7.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendImproving
Δ7d
-0.5
Δ21d
-1.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
33
34% active weight
Current posture
7d trendImproving
Δ7d
+7.7
Δ21d
+21.5
Why this grade
Composite grade C. Momentum 93.3 / Value 41.1 / Sentiment 33.0
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.75B
Beta
0.80
Shares Out
305.38M
P/E (TTM) · Derived
-11.7
P/S (TTM)
29.07
P/FCF (TTM) · Derived
-9.07
Rev YoY
+96.3%
EPS YoY
-7.0%
Gross Margin
+61.0%
Op Margin
-739.7%
Net Debt
-$417.11M
Current Ratio
14.05
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology